Drugs / COFIRASERSEN
COFIRASERSEN
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03647228 | Dec 2018 → Oct 2020 | cystic fibrosis | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04441788 | Dec 2020 → Apr 2021 | chronic bronchitis | Ionis Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COFIRASERSEN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650476 ↗ |
| Known as | ION-827359 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04441788 ↗ |
| Known as | IONIS-ENaCRx | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03647228 ↗ |
| Route | Inhaled | “IONIS-ENaCRx inhaled or nebulized.” NCT03647228 ↗ |